Back to top
more

Five Prime Therapeutics, Inc. (FPRX)

(Delayed Data from NSDQ)

$11.55 USD

11.55
445,354

+0.51 (4.62%)

Updated May 3, 2019 04:00 PM ET

After-Market: $11.54 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

Biotech Stock Roundup: AMGN's Acquisition, ACAD's Regulatory Update & More

The biotech sector was in focus last week with regulatory and pipeline updates from quite a few companies like Amgen (REGN), Acadia (ACAD) and Gilead (GILD).

Why Five Prime Therapeutics (FPRX) Might Surprise This Earnings Season

Five Prime Therapeutics (FPRX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Amgen (AMGN) to Add Stomach Cancer Drug With Five Prime Buyout

Amgen (AMGN) inks a $1.9-billion deal to acquire clinical-stage biotech, Five Prime Therapeutics, to boost its oncology pipeline.

Sweta Killa headshot

ETFs to Tap Amgen's Drive for Cancer Deal

Amgen (AMGN) has agreed to buy Five Prime Therapeutics (FPRX) for $1.9 billion.

Five Prime Therapeutics (FPRX) Stock Jumps 78.7%: Will It Continue to Soar?

Five Prime Therapeutics (FPRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Five Prime Therapeutics (FPRX) Expected to Beat Earnings Estimates: Should You Buy?

Five Prime Therapeutics (FPRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Are Options Traders Betting on a Big Move in Five Prime (FPRX) Stock?

Investors need to pay close attention to Five Prime (FPRX) stock based on the movements in the options market lately.

Five Prime Therapeutics (FPRX) Reports Q3 Loss, Lags Revenue Estimates

Five Prime Therapeutics (FPRX) delivered earnings and revenue surprises of -21.31% and -41.49%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Will Five Prime Therapeutics (FPRX) Report Negative Q3 Earnings? What You Should Know

Five Prime Therapeutics (FPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Five Prime (FPRX) Looks Good: Stock Adds 5.1% in Session

Five Prime (FPRX) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

Five Prime Therapeutics (FPRX) Reports Q2 Loss, Misses Revenue Estimates

Five Prime Therapeutics (FPRX) delivered earnings and revenue surprises of 31.43% and -22.76%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Five Prime Therapeutics (FPRX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Five Prime Therapeutics (FPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Five Prime Therapeutics (FPRX) Report Negative Q2 Earnings? What You Should Know

Five Prime Therapeutics (FPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Is Five Prime Therapeutics (FPRX) Stock a Solid Choice Right Now?

Five Prime Therapeutics (FPRX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Five Prime Therapeutics (FPRX) Reports Q4 Loss, Misses Revenue Estimates

Five Prime Therapeutics (FPRX) delivered earnings and revenue surprises of 8.25% and -20.66%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Five Prime Therapeutics (FPRX) Reports Q3 Loss, Misses Revenue Estimates

Five Prime Therapeutics (FPRX) delivered earnings and revenue surprises of -8.42% and -31.02%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Five Prime Therapeutics (FPRX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Five Prime Therapeutics (FPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Five Prime Therapeutics (FPRX) Reports Q2 Loss, Misses Revenue Estimates

Five Prime Therapeutics (FPRX) delivered earnings and revenue surprises of -15.12% and -39.71%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Five Prime Therapeutics (FPRX) Looks Good: Stock Adds 9.2% in Session

Five Prime Therapeutics (FPRX) shares rose more than 9% in the last trading session, amid huge volumes.

Five Prime Therapeutics (FPRX) Reports Q1 Loss, Misses Revenue Estimates

Five Prime Therapeutics (FPRX) delivered earnings and revenue surprises of 4.67% and -6.36%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Five Prime Therapeutics (FPRX) Q1 Earnings Expected to Decline

Five Prime Therapeutics (FPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Five Prime Therapeutics Continue to Surge Higher?

As of late, it has definitely been a great time to be an investor in Five Prime Therapeutics.

MacroGenics Up on Lifting of Partial Hold on Cancer Candidate

MacroGenics' (MGNX) shares rise as the FDA lifts partial clinical hold on its early-stage cancer candidate, MGD009, placed in December last year.

Five Prime Therapeutics, Inc. (FPRX) Shares March Higher, Can It Continue?

As of late, it has definitely been a great time to be an investor in Five Prime Therapeutics, Inc. (FPRX).

Five Prime Therapeutics (FPRX) Reports Q3 Loss, Misses Revenue Estimates

Five Prime Therapeutics (FPRX) delivered earnings and revenue surprises of -17.09% and -22.56%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?